Beneficial effects of UDCA and norUDCA in a rodent model of steatosis are linked to modulation of GPBAR1/FXR signaling

Bile acids and their receptors in metabolic disorders

(2021) Stefano Fiorucci et al.   PROGRESS IN LIPID RESEARCH

Diet-Induced Models of Non-Alcoholic Fatty Liver Disease: Food for Thought on Sugar, Fat, and Cholesterol

(2021) James M. Eng et al.   Cells

Linking liver metabolic and vascular disease via bile acid signaling

(2021) Stefano Fiorucci et al.   TRENDS IN MOLECULAR MEDICINE

Cenicriviroc Treatment for Adults with Nonalcoholic Steatohepatitis and Fibrosis: Final Analysis of the Phase 2b CENTAUR Study

(2020) Vlad Ratziu et al.   HEPATOLOGY

Of mice and men: Murine bile acids explain species differences in the regulation of bile acid and cholesterol metabolism

(2020) Sara Straniero et al.   JOURNAL OF LIPID RESEARCH

Serum Bile Acid Levels Before and After Sleeve Gastrectomy and Their Correlation with Obesity-Related Comorbidities

(2019) Stefano De Vuono et al.   OBESITY SURGERY

Transcriptome Analysis of Dual FXR and GPBAR1 Agonism in Rodent Model of NASH Reveals Modulation of Lipid Droplets Formation

(2019) Adriana Carino et al.   Nutrients

A Human-like Bile Acid Pool Induced by Deletion of Cyp2c70 Modulates Effects of Farnesoid X Receptor Activation in Mice

(2019) Jan Freark de Boer et al.   JOURNAL OF LIPID RESEARCH

Potential Adiponectin Receptor Response Modifier Therapeutics

(2019) Laszlo Otvos   Frontiers in Endocrinology

Current Treatment of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis

(2018) Chun Kit Hung et al.   Clinics in Liver Disease

Farnesoid X receptor modulators 2014-present: a patent review

(2018) Valentina Sepe et al.   EXPERT OPINION ON THERAPEUTIC PATENTS

Bile Acid Metabolism in Liver Pathobiology

(2018) John Y. L. Chiang et al.   GENE EXPRESSION

Future trends in the treatment of non-alcoholic steatohepatitis

(2018) Stefano Fiorucci et al.   PHARMACOLOGICAL RESEARCH

Animal models of atherosclerosis

(2017) Besa Emini Veseli et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Suppressed hepatic bile acid signalling despite elevated production of primary and secondary bile acids in NAFLD

(2017) Na Jiao et al.   GUT

Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention

(2017) Zobair Younossi et al.   Nature Reviews Gastroenterology & Hepatology

Hyodeoxycholic acid derivatives as liver X receptor α and G-protein-coupled bile acid receptor agonists

(2017) Simona De Marino et al.   Scientific Reports

BAR502, a dual FXR and GPBAR1 agonist, promotes browning of white adipose tissue and reverses liver steatosis and fibrosis

(2017) Adriana Carino et al.   Scientific Reports

Global Epidemiology of Nonalcoholic Fatty Liver Disease and Perspectives on US Minority Populations

(2016) Zaki A. Sherif et al.   DIGESTIVE DISEASES AND SCIENCES

Cyp2c70 is responsible for the species difference in bile acid metabolism between mice and humans

(2016) Shogo Takahashi et al.   JOURNAL OF LIPID RESEARCH

Management of NAFLD: a stage-based approach

(2016) Mary E. Rinella et al.   Nature Reviews Gastroenterology & Hepatology

Potential of nor-Ursodeoxycholic Acid in Cholestatic and Metabolic Disorders

(2015) Michael Trauner et al.   DIGESTIVE DISEASES

Nonalcoholic Fatty Liver Disease

(2015) Mary E. Rinella   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Intestine-selective farnesoid X receptor inhibition improves obesity-related metabolic dysfunction

(2015) Changtao Jiang et al.   Nature Communications

Design, Synthesis, and Biological Evaluation of Potent Dual Agonists of Nuclear and Membrane Bile Acid Receptors

(2014) Claudio D’Amore et al.   JOURNAL OF MEDICINAL CHEMISTRY

Exploitation of Cholane Scaffold for the Discovery of Potent and Selective Farnesoid X Receptor (FXR) and G-Protein Coupled Bile Acid Receptor 1 (GP-BAR1) Ligands

(2014) Carmen Festa et al.   JOURNAL OF MEDICINAL CHEMISTRY

Modification on Ursodeoxycholic Acid (UDCA) Scaffold. Discovery of Bile Acid Derivatives As Selective Agonists of Cell-Surface G-Protein Coupled Bile Acid Receptor 1 (GP-BAR1)

(2014) Valentina Sepe et al.   JOURNAL OF MEDICINAL CHEMISTRY

Incisterols, highly degraded marine sterols, are a new chemotype of PXR agonists

(2014) Giuseppina Chianese et al.   STEROIDS

Nonalcoholic fatty liver disease: an emerging threat to obese and diabetic individuals

(2013) Howard C. Masuoka et al.   Annals of the New York Academy of Sciences

The role of Ursodeoxycholic acid in non-alcoholic steatohepatitis: a systematic review

(2013) Zun Xiang et al.   BMC GASTROENTEROLOGY

Adiponectin Mediates the Metabolic Effects of FGF21 on Glucose Homeostasis and Insulin Sensitivity in Mice

(2013) Zhuofeng Lin et al.   Cell Metabolism

Dissociation of Intestinal and Hepatic Activities of FXR and LXR  Supports Metabolic Effects of Terminal Ileum Interposition in Rodents

(2013) A. Mencarelli et al.   DIABETES

Extrahepatic complications of nonalcoholic fatty liver disease

(2013) Matthew J. Armstrong et al.   HEPATOLOGY

Effect of Statin Therapy on the Progression of Common Carotid Artery Intima-Media Thickness: An Updated Systematic Review and Meta-Analysis of Randomized Controlled Trials

(2012) Yubei Huang et al.   Journal of Atherosclerosis and Thrombosis

Treatment of NASH with ursodeoxycholic acid: Pro

(2012) Vlad Ratziu   Clinics and Research in Hepatology and Gastroenterology

High-dose ursodeoxycholic acid therapy for nonalcoholic steatohepatitis: a double-blind, randomized, placebo-controlled trial

(2010) Ulrich F. H. Leuschner et al.   HEPATOLOGY

Serum total adiponectin in nonalcoholic fatty liver disease: a systematic review and meta-analysis

(2010) Stergios A. Polyzos et al.   METABOLISM-CLINICAL AND EXPERIMENTAL

The Bile Acid Sensor FXR Protects against Dyslipidemia and Aortic Plaques Development Induced by the HIV Protease Inhibitor Ritonavir in Mice

(2010) Andrea Mencarelli et al.   PLoS One

Pathogenesis of non-alcoholic fatty liver disease

(2009) J. K. Dowman et al.   QJM-AN INTERNATIONAL JOURNAL OF MEDICINE